Sky and Space Global completes critical design review


Published 08-SEP-2016 16:07 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Another milestone has been ticked off by Sky and Space Global (ASX:SAS) as the Critical Design Review (CDR) stage for its nano-satellites has been successfully completed.

The CDR was carried out by leading European aerospace construction partner GomSpace, who conducted independent technical reviews and validation testing that was required for SAS to proceed with its technology and designs.

The process involved review of the schedule, overall design, altitude control performance, and system budgets (mass, power and link).

No major issues were identified, with the project progressing as scheduled.

SAS will now commence assembly and integration of its ‘3 diamonds’ nano-satellites that are scheduled for completion mid-January 2017.

Which will then be followed by on the ground testing of the nano-satellite hardware, software and communications systems.

Today’s positive news flows on from SAS receiving technical validation for its communications software earlier in the week.

The contracted launch date for the satellites is set for Q2 2017 to which SAS is fully funded up until including the commercial testing in space, following a recent oversubscribed $4.5M capital raising.

Initial customers are already secured for the bandwidth the ‘3 diamonds’ will produce, allowing for near term revenue generation.

However, how much revenue will be generated and an exact date is yet to be determined, so seek professional financial advice if considering this stock for your portfolio.

SAS aims to have a global constellation of nano-satellites providing low cost communication solution for remote locations.

SAS still has a way to go in commercialising its product and there is no guarantee it will lead be a success so please display caution and seeking expert advice prior to making any investment decision.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free